nodes	percent_of_prediction	percent_of_DWPC	metapath
Apomorphine—DRD5—eyelid—skin cancer	0.0852	0.261	CbGeAlD
Apomorphine—DRD1—nerve—skin cancer	0.0173	0.053	CbGeAlD
Apomorphine—Pain in extremity—Vismodegib—skin cancer	0.0154	0.0302	CcSEcCtD
Apomorphine—Dehydration—Vismodegib—skin cancer	0.0143	0.0281	CcSEcCtD
Apomorphine—HTR2A—hindlimb—skin cancer	0.0111	0.034	CbGeAlD
Apomorphine—HTR1B—blood vessel—skin cancer	0.011	0.0337	CbGeAlD
Apomorphine—HTR1D—blood vessel—skin cancer	0.0107	0.0327	CbGeAlD
Apomorphine—CALY—head—skin cancer	0.0106	0.0325	CbGeAlD
Apomorphine—DRD2—nerve—skin cancer	0.0102	0.0313	CbGeAlD
Apomorphine—HTR2A—appendage—skin cancer	0.00953	0.0291	CbGeAlD
Apomorphine—Pain in extremity—Vemurafenib—skin cancer	0.00951	0.0187	CcSEcCtD
Apomorphine—Swelling—Imiquimod—skin cancer	0.0092	0.0181	CcSEcCtD
Apomorphine—Back pain—Vismodegib—skin cancer	0.00897	0.0176	CcSEcCtD
Apomorphine—Pain in extremity—Imiquimod—skin cancer	0.00811	0.0159	CcSEcCtD
Apomorphine—Arthralgia—Vismodegib—skin cancer	0.00789	0.0155	CcSEcCtD
Apomorphine—CALY—lymph node—skin cancer	0.00745	0.0228	CbGeAlD
Apomorphine—ADRA1D—epithelium—skin cancer	0.00695	0.0213	CbGeAlD
Apomorphine—Musculoskeletal discomfort—Vismodegib—skin cancer	0.00689	0.0135	CcSEcCtD
Apomorphine—Sweating increased—Imiquimod—skin cancer	0.00683	0.0134	CcSEcCtD
Apomorphine—HTR2A—nerve—skin cancer	0.00676	0.0207	CbGeAlD
Apomorphine—DRD5—lymphoid tissue—skin cancer	0.00668	0.0204	CbGeAlD
Apomorphine—Fatigue—Vismodegib—skin cancer	0.00652	0.0128	CcSEcCtD
Apomorphine—Constipation—Vismodegib—skin cancer	0.00647	0.0127	CcSEcCtD
Apomorphine—DRD5—female reproductive system—skin cancer	0.00644	0.0197	CbGeAlD
Apomorphine—Urinary tract infection—Imiquimod—skin cancer	0.00608	0.0119	CcSEcCtD
Apomorphine—HTR2A—endothelium—skin cancer	0.00575	0.0176	CbGeAlD
Apomorphine—DRD3—head—skin cancer	0.00574	0.0176	CbGeAlD
Apomorphine—ADRA2C—nipple—skin cancer	0.00565	0.0173	CbGeAlD
Apomorphine—Back pain—Vemurafenib—skin cancer	0.00554	0.0109	CcSEcCtD
Apomorphine—Rhinorrhoea—Docetaxel—skin cancer	0.0055	0.0108	CcSEcCtD
Apomorphine—HTR1D—connective tissue—skin cancer	0.00548	0.0167	CbGeAlD
Apomorphine—Asthenia—Vismodegib—skin cancer	0.00543	0.0107	CcSEcCtD
Apomorphine—DRD5—head—skin cancer	0.00538	0.0165	CbGeAlD
Apomorphine—Pruritus—Vismodegib—skin cancer	0.00535	0.0105	CcSEcCtD
Apomorphine—HTR2A—blood vessel—skin cancer	0.00531	0.0162	CbGeAlD
Apomorphine—Flushing—Imiquimod—skin cancer	0.00521	0.0102	CcSEcCtD
Apomorphine—Diarrhoea—Vismodegib—skin cancer	0.00518	0.0102	CcSEcCtD
Apomorphine—ADRA1D—female reproductive system—skin cancer	0.00517	0.0158	CbGeAlD
Apomorphine—Swelling—Fluorouracil—skin cancer	0.00508	0.00997	CcSEcCtD
Apomorphine—Mental disorder—Imiquimod—skin cancer	0.00492	0.00965	CcSEcCtD
Apomorphine—Arthralgia—Vemurafenib—skin cancer	0.00488	0.00958	CcSEcCtD
Apomorphine—Vomiting—Vismodegib—skin cancer	0.00481	0.00945	CcSEcCtD
Apomorphine—Back pain—Imiquimod—skin cancer	0.00473	0.00928	CcSEcCtD
Apomorphine—HTR2B—skin of body—skin cancer	0.0046	0.0141	CbGeAlD
Apomorphine—Dehydration—Temozolomide—skin cancer	0.00452	0.00888	CcSEcCtD
Apomorphine—ADRA2A—nipple—skin cancer	0.00451	0.0138	CbGeAlD
Apomorphine—Nausea—Vismodegib—skin cancer	0.00449	0.00883	CcSEcCtD
Apomorphine—Pneumonia—Bleomycin—skin cancer	0.00447	0.00877	CcSEcCtD
Apomorphine—Injection site reaction—Docetaxel—skin cancer	0.00443	0.00869	CcSEcCtD
Apomorphine—ADRA1B—head—skin cancer	0.00441	0.0135	CbGeAlD
Apomorphine—Syncope—Imiquimod—skin cancer	0.00438	0.0086	CcSEcCtD
Apomorphine—Hypotension—Vemurafenib—skin cancer	0.00437	0.00858	CcSEcCtD
Apomorphine—ADRA1D—head—skin cancer	0.00432	0.0132	CbGeAlD
Apomorphine—Loss of consciousness—Imiquimod—skin cancer	0.00429	0.00843	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00426	0.00836	CcSEcCtD
Apomorphine—Pneumonia—Dactinomycin—skin cancer	0.00417	0.00818	CcSEcCtD
Apomorphine—Arthralgia—Imiquimod—skin cancer	0.00416	0.00817	CcSEcCtD
Apomorphine—Chest pain—Imiquimod—skin cancer	0.00416	0.00817	CcSEcCtD
Apomorphine—Anxiety—Imiquimod—skin cancer	0.00414	0.00814	CcSEcCtD
Apomorphine—DRD1—head—skin cancer	0.00411	0.0126	CbGeAlD
Apomorphine—Sweating increased—Temozolomide—skin cancer	0.00409	0.00804	CcSEcCtD
Apomorphine—Fatigue—Vemurafenib—skin cancer	0.00403	0.00791	CcSEcCtD
Apomorphine—Nasopharyngitis—Fluorouracil—skin cancer	0.00401	0.00786	CcSEcCtD
Apomorphine—Constipation—Vemurafenib—skin cancer	0.004	0.00785	CcSEcCtD
Apomorphine—HTR1B—female reproductive system—skin cancer	0.00399	0.0122	CbGeAlD
Apomorphine—Oedema—Imiquimod—skin cancer	0.00399	0.00783	CcSEcCtD
Apomorphine—Shock—Imiquimod—skin cancer	0.00392	0.0077	CcSEcCtD
Apomorphine—HTR1D—female reproductive system—skin cancer	0.00386	0.0118	CbGeAlD
Apomorphine—Hyperhidrosis—Imiquimod—skin cancer	0.00385	0.00757	CcSEcCtD
Apomorphine—HTR2C—female reproductive system—skin cancer	0.00382	0.0117	CbGeAlD
Apomorphine—HTR2A—neck—skin cancer	0.0038	0.0116	CbGeAlD
Apomorphine—Angina pectoris—Fluorouracil—skin cancer	0.00377	0.0074	CcSEcCtD
Apomorphine—Pneumonia—Temozolomide—skin cancer	0.00377	0.0074	CcSEcCtD
Apomorphine—Flushing—Bleomycin—skin cancer	0.0037	0.00727	CcSEcCtD
Apomorphine—Swelling—Docetaxel—skin cancer	0.00366	0.0072	CcSEcCtD
Apomorphine—Urinary tract infection—Temozolomide—skin cancer	0.00364	0.00715	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Imiquimod—skin cancer	0.00363	0.00713	CcSEcCtD
Apomorphine—Insomnia—Imiquimod—skin cancer	0.00361	0.00708	CcSEcCtD
Apomorphine—HTR2B—female reproductive system—skin cancer	0.00359	0.011	CbGeAlD
Apomorphine—Cardiac failure congestive—Docetaxel—skin cancer	0.00356	0.007	CcSEcCtD
Apomorphine—Dyspnoea—Imiquimod—skin cancer	0.00355	0.00698	CcSEcCtD
Apomorphine—Somnolence—Imiquimod—skin cancer	0.00354	0.00696	CcSEcCtD
Apomorphine—Pneumonia—Fluorouracil—skin cancer	0.00347	0.00682	CcSEcCtD
Apomorphine—Flushing—Dactinomycin—skin cancer	0.00345	0.00678	CcSEcCtD
Apomorphine—Fatigue—Imiquimod—skin cancer	0.00344	0.00675	CcSEcCtD
Apomorphine—Urinary tract infection—Fluorouracil—skin cancer	0.00336	0.00659	CcSEcCtD
Apomorphine—Asthenia—Vemurafenib—skin cancer	0.00335	0.00659	CcSEcCtD
Apomorphine—Hallucination—Temozolomide—skin cancer	0.00335	0.00657	CcSEcCtD
Apomorphine—HTR1B—head—skin cancer	0.00333	0.0102	CbGeAlD
Apomorphine—Pruritus—Vemurafenib—skin cancer	0.00331	0.00649	CcSEcCtD
Apomorphine—ADRA2C—mammalian vulva—skin cancer	0.0033	0.0101	CbGeAlD
Apomorphine—Feeling abnormal—Imiquimod—skin cancer	0.00329	0.00645	CcSEcCtD
Apomorphine—Pain in extremity—Docetaxel—skin cancer	0.00323	0.00635	CcSEcCtD
Apomorphine—HTR1D—head—skin cancer	0.00323	0.00987	CbGeAlD
Apomorphine—ADRA2A—connective tissue—skin cancer	0.0032	0.00978	CbGeAlD
Apomorphine—Diarrhoea—Vemurafenib—skin cancer	0.0032	0.00628	CcSEcCtD
Apomorphine—HTR2C—head—skin cancer	0.00319	0.00977	CbGeAlD
Apomorphine—Flushing—Temozolomide—skin cancer	0.00312	0.00613	CcSEcCtD
Apomorphine—Dizziness—Vemurafenib—skin cancer	0.00309	0.00607	CcSEcCtD
Apomorphine—Dehydration—Docetaxel—skin cancer	0.00301	0.0059	CcSEcCtD
Apomorphine—HTR2B—head—skin cancer	0.003	0.00918	CbGeAlD
Apomorphine—Vomiting—Vemurafenib—skin cancer	0.00297	0.00584	CcSEcCtD
Apomorphine—Chest pain—Bleomycin—skin cancer	0.00295	0.0058	CcSEcCtD
Apomorphine—Orthostatic hypotension—Docetaxel—skin cancer	0.00295	0.0058	CcSEcCtD
Apomorphine—Mental disorder—Temozolomide—skin cancer	0.00295	0.00579	CcSEcCtD
Apomorphine—Headache—Vemurafenib—skin cancer	0.00293	0.00575	CcSEcCtD
Apomorphine—Nasopharyngitis—Docetaxel—skin cancer	0.00289	0.00568	CcSEcCtD
Apomorphine—Asthenia—Imiquimod—skin cancer	0.00286	0.00562	CcSEcCtD
Apomorphine—Confusional state—Bleomycin—skin cancer	0.00286	0.00561	CcSEcCtD
Apomorphine—Oedema—Bleomycin—skin cancer	0.00283	0.00556	CcSEcCtD
Apomorphine—Back pain—Temozolomide—skin cancer	0.00283	0.00556	CcSEcCtD
Apomorphine—Pruritus—Imiquimod—skin cancer	0.00282	0.00554	CcSEcCtD
Apomorphine—Nausea—Vemurafenib—skin cancer	0.00278	0.00545	CcSEcCtD
Apomorphine—Diarrhoea—Imiquimod—skin cancer	0.00273	0.00536	CcSEcCtD
Apomorphine—Angina pectoris—Docetaxel—skin cancer	0.00272	0.00534	CcSEcCtD
Apomorphine—HTR2A—connective tissue—skin cancer	0.00272	0.00832	CbGeAlD
Apomorphine—HTR1A—head—skin cancer	0.00269	0.00822	CbGeAlD
Apomorphine—Hypotension—Bleomycin—skin cancer	0.00265	0.0052	CcSEcCtD
Apomorphine—Oedema—Dactinomycin—skin cancer	0.00264	0.00519	CcSEcCtD
Apomorphine—Dizziness—Imiquimod—skin cancer	0.00264	0.00518	CcSEcCtD
Apomorphine—ADRA2A—mammalian vulva—skin cancer	0.00263	0.00806	CbGeAlD
Apomorphine—HTR2A—epithelium—skin cancer	0.00258	0.0079	CbGeAlD
Apomorphine—Musculoskeletal discomfort—Bleomycin—skin cancer	0.00258	0.00507	CcSEcCtD
Apomorphine—Vomiting—Imiquimod—skin cancer	0.00253	0.00498	CcSEcCtD
Apomorphine—Dyspnoea—Bleomycin—skin cancer	0.00253	0.00496	CcSEcCtD
Apomorphine—Pneumonia—Docetaxel—skin cancer	0.00251	0.00492	CcSEcCtD
Apomorphine—Headache—Imiquimod—skin cancer	0.0025	0.0049	CcSEcCtD
Apomorphine—Arthralgia—Temozolomide—skin cancer	0.00249	0.00489	CcSEcCtD
Apomorphine—Anxiety—Temozolomide—skin cancer	0.00248	0.00488	CcSEcCtD
Apomorphine—DRD2—head—skin cancer	0.00243	0.00743	CbGeAlD
Apomorphine—Confusional state—Temozolomide—skin cancer	0.00241	0.00473	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.00241	0.00473	CcSEcCtD
Apomorphine—Oedema—Temozolomide—skin cancer	0.00239	0.00469	CcSEcCtD
Apomorphine—Nausea—Imiquimod—skin cancer	0.00237	0.00465	CcSEcCtD
Apomorphine—ADRA2C—head—skin cancer	0.00236	0.00722	CbGeAlD
Apomorphine—Feeling abnormal—Bleomycin—skin cancer	0.00233	0.00458	CcSEcCtD
Apomorphine—Hyperhidrosis—Temozolomide—skin cancer	0.00231	0.00454	CcSEcCtD
Apomorphine—Chest pain—Fluorouracil—skin cancer	0.0023	0.00451	CcSEcCtD
Apomorphine—Fatigue—Dactinomycin—skin cancer	0.00228	0.00447	CcSEcCtD
Apomorphine—ADRA2A—female reproductive system—skin cancer	0.00226	0.0069	CbGeAlD
Apomorphine—Confusional state—Fluorouracil—skin cancer	0.00222	0.00436	CcSEcCtD
Apomorphine—Oedema—Fluorouracil—skin cancer	0.0022	0.00432	CcSEcCtD
Apomorphine—Feeling abnormal—Dactinomycin—skin cancer	0.00218	0.00427	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Temozolomide—skin cancer	0.00218	0.00427	CcSEcCtD
Apomorphine—Insomnia—Temozolomide—skin cancer	0.00216	0.00424	CcSEcCtD
Apomorphine—Dyspnoea—Temozolomide—skin cancer	0.00213	0.00418	CcSEcCtD
Apomorphine—Somnolence—Temozolomide—skin cancer	0.00212	0.00417	CcSEcCtD
Apomorphine—HTR2B—lymph node—skin cancer	0.0021	0.00643	CbGeAlD
Apomorphine—Flushing—Docetaxel—skin cancer	0.00208	0.00408	CcSEcCtD
Apomorphine—Fatigue—Temozolomide—skin cancer	0.00206	0.00404	CcSEcCtD
Apomorphine—Hypotension—Fluorouracil—skin cancer	0.00206	0.00404	CcSEcCtD
Apomorphine—Constipation—Temozolomide—skin cancer	0.00204	0.00401	CcSEcCtD
Apomorphine—Asthenia—Bleomycin—skin cancer	0.00203	0.00399	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.00201	0.00394	CcSEcCtD
Apomorphine—Pruritus—Bleomycin—skin cancer	0.002	0.00393	CcSEcCtD
Apomorphine—Insomnia—Fluorouracil—skin cancer	0.00199	0.00391	CcSEcCtD
Apomorphine—Feeling abnormal—Temozolomide—skin cancer	0.00197	0.00387	CcSEcCtD
Apomorphine—Dyspnoea—Fluorouracil—skin cancer	0.00196	0.00385	CcSEcCtD
Apomorphine—Mental disorder—Docetaxel—skin cancer	0.00196	0.00385	CcSEcCtD
Apomorphine—Somnolence—Fluorouracil—skin cancer	0.00196	0.00384	CcSEcCtD
Apomorphine—HTR2A—female reproductive system—skin cancer	0.00192	0.00587	CbGeAlD
Apomorphine—Asthenia—Dactinomycin—skin cancer	0.0019	0.00372	CcSEcCtD
Apomorphine—ADRA2A—head—skin cancer	0.00188	0.00576	CbGeAlD
Apomorphine—Back pain—Docetaxel—skin cancer	0.00188	0.0037	CcSEcCtD
Apomorphine—Feeling abnormal—Fluorouracil—skin cancer	0.00181	0.00356	CcSEcCtD
Apomorphine—Diarrhoea—Dactinomycin—skin cancer	0.00181	0.00355	CcSEcCtD
Apomorphine—Vomiting—Bleomycin—skin cancer	0.0018	0.00354	CcSEcCtD
Apomorphine—Syncope—Docetaxel—skin cancer	0.00175	0.00343	CcSEcCtD
Apomorphine—Asthenia—Temozolomide—skin cancer	0.00171	0.00337	CcSEcCtD
Apomorphine—Loss of consciousness—Docetaxel—skin cancer	0.00171	0.00336	CcSEcCtD
Apomorphine—Pruritus—Temozolomide—skin cancer	0.00169	0.00332	CcSEcCtD
Apomorphine—Nausea—Bleomycin—skin cancer	0.00168	0.0033	CcSEcCtD
Apomorphine—Vomiting—Dactinomycin—skin cancer	0.00168	0.0033	CcSEcCtD
Apomorphine—Arthralgia—Docetaxel—skin cancer	0.00166	0.00325	CcSEcCtD
Apomorphine—Chest pain—Docetaxel—skin cancer	0.00166	0.00325	CcSEcCtD
Apomorphine—ADRA2C—lymph node—skin cancer	0.00165	0.00506	CbGeAlD
Apomorphine—Diarrhoea—Temozolomide—skin cancer	0.00163	0.00321	CcSEcCtD
Apomorphine—HTR2A—head—skin cancer	0.0016	0.0049	CbGeAlD
Apomorphine—Confusional state—Docetaxel—skin cancer	0.0016	0.00315	CcSEcCtD
Apomorphine—Oedema—Docetaxel—skin cancer	0.00159	0.00312	CcSEcCtD
Apomorphine—Dizziness—Temozolomide—skin cancer	0.00158	0.0031	CcSEcCtD
Apomorphine—Nausea—Dactinomycin—skin cancer	0.00157	0.00308	CcSEcCtD
Apomorphine—Shock—Docetaxel—skin cancer	0.00156	0.00307	CcSEcCtD
Apomorphine—Pruritus—Fluorouracil—skin cancer	0.00156	0.00306	CcSEcCtD
Apomorphine—Vomiting—Temozolomide—skin cancer	0.00152	0.00298	CcSEcCtD
Apomorphine—Diarrhoea—Fluorouracil—skin cancer	0.00151	0.00296	CcSEcCtD
Apomorphine—Headache—Temozolomide—skin cancer	0.0015	0.00294	CcSEcCtD
Apomorphine—Hypotension—Docetaxel—skin cancer	0.00148	0.00292	CcSEcCtD
Apomorphine—Dizziness—Fluorouracil—skin cancer	0.00146	0.00286	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Docetaxel—skin cancer	0.00145	0.00284	CcSEcCtD
Apomorphine—Insomnia—Docetaxel—skin cancer	0.00144	0.00282	CcSEcCtD
Apomorphine—Nausea—Temozolomide—skin cancer	0.00142	0.00279	CcSEcCtD
Apomorphine—Dyspnoea—Docetaxel—skin cancer	0.00142	0.00278	CcSEcCtD
Apomorphine—Somnolence—Docetaxel—skin cancer	0.00141	0.00277	CcSEcCtD
Apomorphine—Vomiting—Fluorouracil—skin cancer	0.0014	0.00275	CcSEcCtD
Apomorphine—Headache—Fluorouracil—skin cancer	0.00138	0.00271	CcSEcCtD
Apomorphine—Fatigue—Docetaxel—skin cancer	0.00137	0.00269	CcSEcCtD
Apomorphine—Constipation—Docetaxel—skin cancer	0.00136	0.00267	CcSEcCtD
Apomorphine—ADRA2A—lymph node—skin cancer	0.00132	0.00404	CbGeAlD
Apomorphine—Feeling abnormal—Docetaxel—skin cancer	0.00131	0.00257	CcSEcCtD
Apomorphine—Nausea—Fluorouracil—skin cancer	0.00131	0.00257	CcSEcCtD
Apomorphine—Asthenia—Docetaxel—skin cancer	0.00114	0.00224	CcSEcCtD
Apomorphine—Pruritus—Docetaxel—skin cancer	0.00112	0.00221	CcSEcCtD
Apomorphine—Diarrhoea—Docetaxel—skin cancer	0.00109	0.00213	CcSEcCtD
Apomorphine—Dizziness—Docetaxel—skin cancer	0.00105	0.00206	CcSEcCtD
Apomorphine—Vomiting—Docetaxel—skin cancer	0.00101	0.00198	CcSEcCtD
Apomorphine—Headache—Docetaxel—skin cancer	0.000995	0.00195	CcSEcCtD
Apomorphine—Nausea—Docetaxel—skin cancer	0.000944	0.00185	CcSEcCtD
Apomorphine—DRD4—Signaling Pathways—FOXO4—skin cancer	9.59e-05	0.000586	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—SHH—skin cancer	9.44e-05	0.000576	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—SUFU—skin cancer	9.39e-05	0.000573	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—RASA1—skin cancer	9.38e-05	0.000572	CbGpPWpGaD
Apomorphine—DRD2—Circadian rythm related genes—IL6—skin cancer	9.37e-05	0.000572	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—FOXO4—skin cancer	9.16e-05	0.000559	CbGpPWpGaD
Apomorphine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	9.13e-05	0.000557	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—SHH—skin cancer	9.11e-05	0.000556	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—SHH—skin cancer	9.06e-05	0.000553	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—RASA1—skin cancer	9.05e-05	0.000553	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—RASA1—skin cancer	9e-05	0.00055	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—SMO—skin cancer	8.94e-05	0.000546	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—PTCH1—skin cancer	8.94e-05	0.000546	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—SHH—skin cancer	8.81e-05	0.000538	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—RASA1—skin cancer	8.76e-05	0.000535	CbGpPWpGaD
Apomorphine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	8.73e-05	0.000533	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—PTGER4—skin cancer	8.71e-05	0.000532	CbGpPWpGaD
Apomorphine—DRD5—Signaling Pathways—TERT—skin cancer	8.68e-05	0.00053	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—SHH—skin cancer	8.67e-05	0.00053	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—FOXO4—skin cancer	8.63e-05	0.000527	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—SMO—skin cancer	8.63e-05	0.000527	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—PTCH1—skin cancer	8.63e-05	0.000527	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—RASA1—skin cancer	8.62e-05	0.000526	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—PTCH1—skin cancer	8.59e-05	0.000524	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—SMO—skin cancer	8.59e-05	0.000524	CbGpPWpGaD
Apomorphine—ADRA2A—Metabolism—ENO2—skin cancer	8.56e-05	0.000523	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—FOXO4—skin cancer	8.52e-05	0.00052	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—FOXO4—skin cancer	8.52e-05	0.00052	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—PTGER4—skin cancer	8.41e-05	0.000513	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—PTGER4—skin cancer	8.36e-05	0.000511	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—PTCH1—skin cancer	8.36e-05	0.00051	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—SMO—skin cancer	8.36e-05	0.00051	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—SMO—skin cancer	8.22e-05	0.000502	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—PTCH1—skin cancer	8.22e-05	0.000502	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—PTGER4—skin cancer	8.13e-05	0.000497	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—PTGER4—skin cancer	8.01e-05	0.000489	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—SHH—skin cancer	8e-05	0.000488	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—RASA1—skin cancer	7.95e-05	0.000485	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—SHH—skin cancer	7.87e-05	0.00048	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—RASA1—skin cancer	7.82e-05	0.000477	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—FOXO4—skin cancer	7.69e-05	0.00047	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—PTCH1—skin cancer	7.58e-05	0.000463	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—SMO—skin cancer	7.58e-05	0.000463	CbGpPWpGaD
Apomorphine—ADRA2B—Hemostasis—NRAS—skin cancer	7.54e-05	0.00046	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—SMO—skin cancer	7.46e-05	0.000455	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—PTCH1—skin cancer	7.46e-05	0.000455	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—FOXO4—skin cancer	7.43e-05	0.000453	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—FOXO4—skin cancer	7.39e-05	0.000451	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—PTGER4—skin cancer	7.38e-05	0.000451	CbGpPWpGaD
Apomorphine—DRD5—Signaling by GPCR—NRAS—skin cancer	7.31e-05	0.000446	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—PTGER4—skin cancer	7.26e-05	0.000443	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—FOXO4—skin cancer	7.18e-05	0.000439	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—SHH—skin cancer	7.16e-05	0.000437	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—RASA1—skin cancer	7.11e-05	0.000434	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—FOXO4—skin cancer	7.07e-05	0.000432	CbGpPWpGaD
Apomorphine—ADRA2C—Hemostasis—NRAS—skin cancer	7.05e-05	0.00043	CbGpPWpGaD
Apomorphine—DRD5—Signaling Pathways—BRAF—skin cancer	6.87e-05	0.00042	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—PTCH1—skin cancer	6.79e-05	0.000414	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—SMO—skin cancer	6.79e-05	0.000414	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—TERT—skin cancer	6.65e-05	0.000406	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—PTGER4—skin cancer	6.61e-05	0.000403	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—FOXO4—skin cancer	6.52e-05	0.000398	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—TERT—skin cancer	6.51e-05	0.000397	CbGpPWpGaD
Apomorphine—ADRA2B—Hemostasis—KRAS—skin cancer	6.49e-05	0.000396	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—FOXO4—skin cancer	6.41e-05	0.000392	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—TERT—skin cancer	6.41e-05	0.000391	CbGpPWpGaD
Apomorphine—DRD5—Signaling by GPCR—KRAS—skin cancer	6.29e-05	0.000384	CbGpPWpGaD
Apomorphine—ADRA2C—Metabolism—ERCC2—skin cancer	6.12e-05	0.000374	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—TERT—skin cancer	6.12e-05	0.000373	CbGpPWpGaD
Apomorphine—ADRA2C—Hemostasis—KRAS—skin cancer	6.06e-05	0.00037	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—FOXO4—skin cancer	5.84e-05	0.000356	CbGpPWpGaD
Apomorphine—ADRA2B—Hemostasis—TP53—skin cancer	5.77e-05	0.000352	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—TERT—skin cancer	5.77e-05	0.000352	CbGpPWpGaD
Apomorphine—ADRA2A—Hemostasis—NRAS—skin cancer	5.72e-05	0.000349	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—TERT—skin cancer	5.69e-05	0.000347	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—TERT—skin cancer	5.69e-05	0.000347	CbGpPWpGaD
Apomorphine—HTR1D—Signaling by GPCR—NRAS—skin cancer	5.6e-05	0.000342	CbGpPWpGaD
Apomorphine—ADRA2B—Hemostasis—HRAS—skin cancer	5.52e-05	0.000337	CbGpPWpGaD
Apomorphine—HTR1B—Signaling by GPCR—NRAS—skin cancer	5.49e-05	0.000335	CbGpPWpGaD
Apomorphine—DRD4—Signaling by GPCR—NRAS—skin cancer	5.4e-05	0.00033	CbGpPWpGaD
Apomorphine—ADRA2C—Hemostasis—TP53—skin cancer	5.39e-05	0.000329	CbGpPWpGaD
Apomorphine—DRD5—Signaling by GPCR—HRAS—skin cancer	5.35e-05	0.000327	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—BRAF—skin cancer	5.27e-05	0.000321	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—BRAF—skin cancer	5.16e-05	0.000315	CbGpPWpGaD
Apomorphine—ADRA2C—Hemostasis—HRAS—skin cancer	5.15e-05	0.000315	CbGpPWpGaD
Apomorphine—HTR2B—Signaling by GPCR—NRAS—skin cancer	5.15e-05	0.000315	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—TERT—skin cancer	5.14e-05	0.000314	CbGpPWpGaD
Apomorphine—DRD5—Signaling by GPCR—IL6—skin cancer	5.12e-05	0.000313	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—BRAF—skin cancer	5.07e-05	0.00031	CbGpPWpGaD
Apomorphine—ADRA2A—Metabolism—ERCC2—skin cancer	4.97e-05	0.000304	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—TERT—skin cancer	4.96e-05	0.000303	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—TERT—skin cancer	4.93e-05	0.000301	CbGpPWpGaD
Apomorphine—ADRA2A—Hemostasis—KRAS—skin cancer	4.93e-05	0.000301	CbGpPWpGaD
Apomorphine—DRD1—Signaling by GPCR—NRAS—skin cancer	4.86e-05	0.000297	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—BRAF—skin cancer	4.84e-05	0.000296	CbGpPWpGaD
Apomorphine—HTR1D—Signaling by GPCR—KRAS—skin cancer	4.82e-05	0.000294	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—TERT—skin cancer	4.8e-05	0.000293	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling by GPCR—NRAS—skin cancer	4.79e-05	0.000293	CbGpPWpGaD
Apomorphine—DRD3—Signaling by GPCR—NRAS—skin cancer	4.79e-05	0.000293	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—TERT—skin cancer	4.72e-05	0.000288	CbGpPWpGaD
Apomorphine—HTR1B—Signaling by GPCR—KRAS—skin cancer	4.72e-05	0.000288	CbGpPWpGaD
Apomorphine—DRD4—Signaling by GPCR—KRAS—skin cancer	4.65e-05	0.000284	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—BRAF—skin cancer	4.57e-05	0.000279	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—BRAF—skin cancer	4.51e-05	0.000275	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—BRAF—skin cancer	4.51e-05	0.000275	CbGpPWpGaD
Apomorphine—HTR2B—Signaling by GPCR—KRAS—skin cancer	4.43e-05	0.000271	CbGpPWpGaD
Apomorphine—ADRA2A—Hemostasis—TP53—skin cancer	4.38e-05	0.000267	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—TERT—skin cancer	4.35e-05	0.000266	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling by GPCR—NRAS—skin cancer	4.33e-05	0.000264	CbGpPWpGaD
Apomorphine—DRD5—Signaling Pathways—NRAS—skin cancer	4.32e-05	0.000264	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—TERT—skin cancer	4.28e-05	0.000262	CbGpPWpGaD
Apomorphine—ADRA2A—Hemostasis—HRAS—skin cancer	4.19e-05	0.000256	CbGpPWpGaD
Apomorphine—DRD1—Signaling by GPCR—KRAS—skin cancer	4.18e-05	0.000255	CbGpPWpGaD
Apomorphine—HTR1A—Signaling by GPCR—NRAS—skin cancer	4.18e-05	0.000255	CbGpPWpGaD
Apomorphine—HTR2C—Signaling by GPCR—NRAS—skin cancer	4.16e-05	0.000254	CbGpPWpGaD
Apomorphine—DRD3—Signaling by GPCR—KRAS—skin cancer	4.13e-05	0.000252	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling by GPCR—KRAS—skin cancer	4.13e-05	0.000252	CbGpPWpGaD
Apomorphine—HTR1D—Signaling by GPCR—HRAS—skin cancer	4.1e-05	0.00025	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—BRAF—skin cancer	4.07e-05	0.000248	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling by GPCR—NRAS—skin cancer	4.04e-05	0.000247	CbGpPWpGaD
Apomorphine—HTR1B—Signaling by GPCR—HRAS—skin cancer	4.01e-05	0.000245	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling by GPCR—NRAS—skin cancer	3.98e-05	0.000243	CbGpPWpGaD
Apomorphine—DRD4—Signaling by GPCR—HRAS—skin cancer	3.95e-05	0.000241	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—BRAF—skin cancer	3.93e-05	0.00024	CbGpPWpGaD
Apomorphine—HTR1D—Signaling by GPCR—IL6—skin cancer	3.92e-05	0.000239	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—BRAF—skin cancer	3.91e-05	0.000239	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—TERT—skin cancer	3.9e-05	0.000238	CbGpPWpGaD
Apomorphine—HTR1B—Signaling by GPCR—IL6—skin cancer	3.84e-05	0.000234	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—BRAF—skin cancer	3.8e-05	0.000232	CbGpPWpGaD
Apomorphine—DRD4—Signaling by GPCR—IL6—skin cancer	3.78e-05	0.000231	CbGpPWpGaD
Apomorphine—HTR2B—Signaling by GPCR—HRAS—skin cancer	3.77e-05	0.00023	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—BRAF—skin cancer	3.74e-05	0.000228	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling by GPCR—KRAS—skin cancer	3.73e-05	0.000227	CbGpPWpGaD
Apomorphine—DRD5—Signaling Pathways—KRAS—skin cancer	3.72e-05	0.000227	CbGpPWpGaD
Apomorphine—ADRA2C—Metabolism—PTGS2—skin cancer	3.67e-05	0.000224	CbGpPWpGaD
Apomorphine—DRD2—Signaling by GPCR—NRAS—skin cancer	3.67e-05	0.000224	CbGpPWpGaD
Apomorphine—HTR2A—Signaling by GPCR—NRAS—skin cancer	3.61e-05	0.00022	CbGpPWpGaD
Apomorphine—HTR2B—Signaling by GPCR—IL6—skin cancer	3.61e-05	0.00022	CbGpPWpGaD
Apomorphine—HTR1A—Signaling by GPCR—KRAS—skin cancer	3.6e-05	0.00022	CbGpPWpGaD
Apomorphine—HTR2C—Signaling by GPCR—KRAS—skin cancer	3.58e-05	0.000218	CbGpPWpGaD
Apomorphine—DRD1—Signaling by GPCR—HRAS—skin cancer	3.55e-05	0.000217	CbGpPWpGaD
Apomorphine—DRD3—Signaling by GPCR—HRAS—skin cancer	3.51e-05	0.000214	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling by GPCR—HRAS—skin cancer	3.51e-05	0.000214	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling by GPCR—KRAS—skin cancer	3.48e-05	0.000212	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—BRAF—skin cancer	3.45e-05	0.000211	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling by GPCR—KRAS—skin cancer	3.42e-05	0.000209	CbGpPWpGaD
Apomorphine—DRD1—Signaling by GPCR—IL6—skin cancer	3.4e-05	0.000208	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—BRAF—skin cancer	3.39e-05	0.000207	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling by GPCR—IL6—skin cancer	3.36e-05	0.000205	CbGpPWpGaD
Apomorphine—DRD3—Signaling by GPCR—IL6—skin cancer	3.36e-05	0.000205	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—NRAS—skin cancer	3.31e-05	0.000202	CbGpPWpGaD
Apomorphine—DRD5—Signaling Pathways—TP53—skin cancer	3.3e-05	0.000202	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—NRAS—skin cancer	3.28e-05	0.000201	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—NRAS—skin cancer	3.24e-05	0.000198	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—NRAS—skin cancer	3.19e-05	0.000195	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling by GPCR—HRAS—skin cancer	3.17e-05	0.000193	CbGpPWpGaD
Apomorphine—DRD5—Signaling Pathways—HRAS—skin cancer	3.16e-05	0.000193	CbGpPWpGaD
Apomorphine—DRD2—Signaling by GPCR—KRAS—skin cancer	3.16e-05	0.000193	CbGpPWpGaD
Apomorphine—HTR2A—Signaling by GPCR—KRAS—skin cancer	3.11e-05	0.00019	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—BRAF—skin cancer	3.09e-05	0.000188	CbGpPWpGaD
Apomorphine—HTR1A—Signaling by GPCR—HRAS—skin cancer	3.06e-05	0.000187	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—NRAS—skin cancer	3.04e-05	0.000186	CbGpPWpGaD
Apomorphine—HTR2C—Signaling by GPCR—HRAS—skin cancer	3.04e-05	0.000186	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling by GPCR—IL6—skin cancer	3.03e-05	0.000185	CbGpPWpGaD
Apomorphine—DRD5—Signaling Pathways—IL6—skin cancer	3.02e-05	0.000185	CbGpPWpGaD
Apomorphine—ADRA2A—Metabolism—PTGS2—skin cancer	2.98e-05	0.000182	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling by GPCR—HRAS—skin cancer	2.96e-05	0.000181	CbGpPWpGaD
Apomorphine—HTR1A—Signaling by GPCR—IL6—skin cancer	2.93e-05	0.000179	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling by GPCR—HRAS—skin cancer	2.91e-05	0.000178	CbGpPWpGaD
Apomorphine—HTR2C—Signaling by GPCR—IL6—skin cancer	2.91e-05	0.000178	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—NRAS—skin cancer	2.87e-05	0.000175	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—KRAS—skin cancer	2.85e-05	0.000174	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—NRAS—skin cancer	2.83e-05	0.000173	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—NRAS—skin cancer	2.83e-05	0.000173	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling by GPCR—IL6—skin cancer	2.83e-05	0.000173	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—KRAS—skin cancer	2.83e-05	0.000173	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—KRAS—skin cancer	2.79e-05	0.00017	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling by GPCR—IL6—skin cancer	2.79e-05	0.00017	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—KRAS—skin cancer	2.74e-05	0.000168	CbGpPWpGaD
Apomorphine—DRD2—Signaling by GPCR—HRAS—skin cancer	2.68e-05	0.000164	CbGpPWpGaD
Apomorphine—HTR2A—Signaling by GPCR—HRAS—skin cancer	2.64e-05	0.000161	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—KRAS—skin cancer	2.62e-05	0.00016	CbGpPWpGaD
Apomorphine—DRD2—Signaling by GPCR—IL6—skin cancer	2.57e-05	0.000157	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—NRAS—skin cancer	2.56e-05	0.000156	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—TP53—skin cancer	2.53e-05	0.000155	CbGpPWpGaD
Apomorphine—HTR2A—Signaling by GPCR—IL6—skin cancer	2.53e-05	0.000154	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—TP53—skin cancer	2.48e-05	0.000151	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—KRAS—skin cancer	2.47e-05	0.000151	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—NRAS—skin cancer	2.47e-05	0.000151	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—NRAS—skin cancer	2.46e-05	0.00015	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—TP53—skin cancer	2.44e-05	0.000149	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—KRAS—skin cancer	2.44e-05	0.000149	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—KRAS—skin cancer	2.44e-05	0.000149	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—HRAS—skin cancer	2.42e-05	0.000148	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—HRAS—skin cancer	2.4e-05	0.000147	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—NRAS—skin cancer	2.39e-05	0.000146	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—HRAS—skin cancer	2.37e-05	0.000145	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—NRAS—skin cancer	2.35e-05	0.000144	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—HRAS—skin cancer	2.33e-05	0.000142	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—TP53—skin cancer	2.33e-05	0.000142	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—IL6—skin cancer	2.32e-05	0.000141	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—IL6—skin cancer	2.3e-05	0.00014	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—IL6—skin cancer	2.27e-05	0.000139	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—IL6—skin cancer	2.23e-05	0.000136	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—HRAS—skin cancer	2.23e-05	0.000136	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—KRAS—skin cancer	2.2e-05	0.000134	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—TP53—skin cancer	2.2e-05	0.000134	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—NRAS—skin cancer	2.17e-05	0.000132	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—TP53—skin cancer	2.17e-05	0.000132	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—TP53—skin cancer	2.17e-05	0.000132	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—NRAS—skin cancer	2.13e-05	0.00013	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—IL6—skin cancer	2.13e-05	0.00013	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—KRAS—skin cancer	2.12e-05	0.00013	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—KRAS—skin cancer	2.11e-05	0.000129	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—HRAS—skin cancer	2.1e-05	0.000128	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—HRAS—skin cancer	2.07e-05	0.000127	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—HRAS—skin cancer	2.07e-05	0.000127	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—KRAS—skin cancer	2.06e-05	0.000126	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—KRAS—skin cancer	2.02e-05	0.000124	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—IL6—skin cancer	2.01e-05	0.000123	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—IL6—skin cancer	1.98e-05	0.000121	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—IL6—skin cancer	1.98e-05	0.000121	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—TP53—skin cancer	1.96e-05	0.000119	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—NRAS—skin cancer	1.94e-05	0.000118	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—TP53—skin cancer	1.89e-05	0.000115	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—TP53—skin cancer	1.88e-05	0.000115	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—HRAS—skin cancer	1.87e-05	0.000114	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—KRAS—skin cancer	1.87e-05	0.000114	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—KRAS—skin cancer	1.84e-05	0.000112	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—TP53—skin cancer	1.83e-05	0.000112	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—HRAS—skin cancer	1.81e-05	0.00011	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—TP53—skin cancer	1.8e-05	0.00011	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—HRAS—skin cancer	1.8e-05	0.00011	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—IL6—skin cancer	1.79e-05	0.000109	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—HRAS—skin cancer	1.75e-05	0.000107	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—IL6—skin cancer	1.73e-05	0.000106	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—HRAS—skin cancer	1.72e-05	0.000105	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—IL6—skin cancer	1.72e-05	0.000105	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—IL6—skin cancer	1.67e-05	0.000102	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—KRAS—skin cancer	1.67e-05	0.000102	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—TP53—skin cancer	1.66e-05	0.000101	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—IL6—skin cancer	1.65e-05	0.0001	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—TP53—skin cancer	1.63e-05	9.96e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—HRAS—skin cancer	1.59e-05	9.68e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—HRAS—skin cancer	1.56e-05	9.52e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—IL6—skin cancer	1.52e-05	9.26e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—IL6—skin cancer	1.49e-05	9.12e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—TP53—skin cancer	1.48e-05	9.06e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—HRAS—skin cancer	1.42e-05	8.67e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—IL6—skin cancer	1.36e-05	8.29e-05	CbGpPWpGaD
